The American Society of Clinical Oncology (ASCO) Annual Meeting is an annual event for the global oncology community, which will be held from May 31 to June 4 local time. The ASCO Annual Meeting is dedicated to the prevention, treatment and improvement of patient management of cancer, featuring the presentation of basic research and the latest clinical research on tumors, and discussing the current international advanced treatment methods. At this meeting, 3 Oral Abstract Sessions, 4 Rapid Oral Abstract Sessions, and 17 Poster Sessions were selected as Chinese studies related to hematological malignancies. Let's look forward to the Voice of China at the ASCO Annual Meeting!
Oral Abstract Session
Description No.: 6505
英文标题：Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Chinese title: A phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Speaker and Affiliation: Wang Ying, Hospital of Blood Diseases, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences)
Abstract: 7002
英文标题：CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma.
Chinese title: CLAMP study: A phase II prospective study of camrelizumab in combination with pegaspargas, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma
Speaker and Affiliation: Liu Tao, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Abstract Number: LBA7003
英文标题：Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.
Chinese title: Chidamide in combination with R-CHOP in untreated diffuse large B-cell lymphoma with dual expression of MYC and BCL2: an interim analysis of the phase III DEB study
Speaker and Affiliation: Zhao Weilin, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Rapid Oral Abstract Session
Description No.: 6510
英文标题：Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS).
Chinese title: Recent results from a phase II study of IMM01 in combination with azacitidine (AZA) as first-line treatment in adult patients with high-risk myelodysplastic syndrome (MDS).
Speaker and Affiliation: Wei Yang, Shengjing Hospital, China Medical University
Abstract: 6515
英文标题：Safety and efficacy of CD7-CAR-T cell in patients with relapsed/refractory T-lymphoblastic leukemia/lymphoma: Phase I dose-escalation/dose-expansion study.
Chinese title: Safety and efficacy of CD7 CAR-T cells in the treatment of patients with relapsed/refractory T-lymphoblastic leukemia/lymphoma: a phase I dose escalation/dose expansion study
Speaker and affiliation: Lijuan Hu, Peking University People's Hospital
Abstract:7017
英文标题：Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity.
Chinese Title: Timdarpacept (IMM01) in Combination With Tislelizumab in Classical Hodgkin Lymphoma Failing Prior Anti-PD-1 Therapy: An Open-label, Multicenter, Phase II Study to Evaluate Safety and Preliminary Antitumor Activity (IMM01-04)
Speaker and unit: Zhenjiu Wang / The unit is not announced on the official website
Description No.: 7511
英文标题：OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS).
Chinese title: OriCAR-017 is a novel GPRC5D-targeting CAR-T for the treatment of patients with relapsed/refractory multiple myeloma: long-term follow-up results of a phase I study (POLARIS).
Speaker and Affiliation: Fu Shan, The First Affiliated Hospital of Zhejiang University School of Medicine
Poster Session
Abstract No.: 6518
英文标题：Phase I study of functionally enhanced CD33 CAR T cells in patients with relapsed or refractory acute myeloid leukemia.
Chinese title: A phase I study of functionally enhanced CD33 CAR-T cells in patients with relapsed or refractory acute myeloid leukemia
Speaker and Affiliation: Jing Pan, Beijing Boren Hospital
Abstract: 6524
英文标题：Molecular characterization and biomarker identification in pediatric B-cell acute lymphoblastic leukemia.
Chinese title: Molecular characterization and biomarker identification of B-cell acute lymphoblastic leukemia in children
Speaker & Affiliation: Du Yu, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology
Abstract: 6541
英文标题：Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia.
Chinese title: Safety and efficacy of the novel BCL-2 inhibitor lisaftoclax in combination with azacitidine in the treatment of naïve, relapsed or refractory acute myeloid leukemia
Speaker and Affiliation: Wang Huafeng, The First Affiliated Hospital of Zhejiang University School of Medicine
Abstract: 6545
英文标题：A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia.
Chinese title: A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in the treatment of newly diagnosed acute myeloid leukemia
Speaker and Affiliation: Han Yue, The First Affiliated Hospital of Soochow University
Description Number: 6573
英文标题：Efficacy and safety of ruxolitinib in patients with lower risk myelofibrosis: A single-arm, exploratory and prospective study.
Chinese title: Efficacy and safety of ruxolitinib in patients with low-risk myelofibrosis: a single-arm, exploratory and prospective study
Speaker and Affiliation: Shiwei Hu The First Affiliated Hospital of Zhejiang University School of Medicine
Abstract:7022
英文标题：EX103: A newly designed CD20×CD3 molecule in heavily pre-treated patients with B-cell non-Hodgkin lymphoma from a phase I/II trial.
Chinese title: A Phase I/II trial of EX103, a newly designed CD20×CD3 molecule, in patients with B-cell non-Hodgkin lymphoma who have received multiple prior lines of therapy
Speaker and affiliation: Mingyuan Sun Peking Union Medical College Hospital
Abstract:7027
英文标题：A phase 1 study of LY007, a novel anti-CD20 CAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Chinese title: A phase I study of LY007, a novel anti-CD20 CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Speaker & Affiliation: Rong Shen Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Abstract: 7040
英文标题：Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Chinese title: A phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Speaker & Affiliation: Yang Xie Peking University Cancer Hospital
Abstract: 7057
英文标题：A novel and selective oral PI3Kα/δ inhibitor, TQ-B3525, in patients with relapsed and/or refractory follicular lymphoma: A phase II, single-arm, open-label study.
Chinese Title: TQ-B3525, a novel selective oral PI3Kα/δ inhibitor, in patients with relapsed and/or refractory follicular lymphoma: a phase II, single-arm, open-label study
Speaker and unit: Huaqing Wang / The unit is not announced on the official website
Abstract No.: 7059
英文标题：A phase II multicenter study of abexinostat, an oral histone deacetylase inhibitor, in patients with relapsed/refractory follicular lymphoma.
Chinese title: A phase II multicenter study of an oral histone deacetylase inhibitor ibelastat in patients with relapsed/refractory follicular lymphoma
Speaker and Affiliation: Yuankai Shi, Cancer Hospital, Chinese Academy of Medical Sciences
Abstract:7060
英文标题：Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.
Chinese Title: Preliminary results of a phase I study IMM0306 the treatment of patients with relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma
Speaker and Affiliation: Jianliang Yang Peking Union Medical College Hospital
Abstract:7062
英文标题：Frontline treatment with zanubrutinib plus rituximab (ZR) followed by short course R-DHAOx in patients with mantle cell lymphoma (MCL): Results of the phase II CHESS clinical trial.
Chinese title: Short-course R-DHAOx therapy in patients with mantle cell lymphoma (MCL) after first-line treatment with zanubrutinib in combination with rituximab (ZR): Results of the phase II CHESS clinical trial
Speaker and Affiliation: Cai Qingqing, Sun Yat-sen University Cancer Center
Abstract:7064
英文标题：A phase 1 study of SHR-A1912, a CD79b targeted antibody-drug conjugate (ADC), in patients (pts) with B-cell non-Hodgkin lymphoma (B-NHL).
Chinese title: A phase I study of SHR-A1912, an antibody-drug conjugate (ADC) targeting CD79b, in B-cell non-Hodgkin lymphoma (B-NHL).
Speaker and Affiliation: Zengjun Li Shandong Provincial Cancer Hospital
Abstract:7065
英文标题：Selinexor combined with tislelizumab in patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL): Results of dose escalation of cohort C, from a multicenter, single-arm, phase I/II study (TOUCH).
Chinese title: Selinexor in combination with tislelizumab in relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL): Cohort C dose escalation results from a multicenter, single-arm, phase I/II study (TOUCH).
Speaker and Affiliation: Chuanxu Liu, Fudan University Cancer Hospital
Abstract Number: LBA7074
英文标题：HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial.
Chinese title: HDAC I/IIb selective inhibitor praisstat mesylate in the treatment of relapsed and refractory diffuse large B-cell lymphoma: a single-agent phase IIa trial
Speaker and unit: Lijuan Chen / The unit is not announced on the official website
Description No.: 7075
英文标题：P-GEMOX with sequential or sandwiched radiotherapy for early-stage extranodal natural killer/T-cell lymphoma.
Chinese title: P-GEMOX combined with sequential or sandwich radiotherapy in the treatment of early extranodal NK/T-cell lymphoma
Speaker and unit: Mixue Xie / currently unannounced on the official website
Abstract Number: TPS7098
英文标题：An open label, single arm, multicenter phase II study of the efficacy and safety of LP-168 monotherapy for relapsed or refractory mantle cell lymphoma.
Chinese title: An open-label, single-arm, multicenter phase II study of the efficacy and safety of LP-168 monotherapy in relapsed or refractory mantle cell lymphoma
Speaker and Affiliation: Yuqin Song, Peking University Cancer Hospital
Sort by report type and summary number, and leave us a message if you miss something
整理：Cherry排版：Yvonee执行：Quinta
Yimaitong is a professional online doctor platform, and the mission of the platform is to "sense the pulse of the world's medicine and help China's clinical decision-making". Yimaitong has a series of products such as "Clinical Guidelines", "Medication Reference", "Medical Literature King", "Yizhiyuan", "eYantong" and "ePulse", which fully meet the needs of medical workers in clinical decision-making, obtaining new knowledge and improving scientific research efficiency.
Disclaimer: This platform aims to deliver more medical information to healthcare professionals. The content published on this platform should not be used as a substitute for professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice. If such information is used for purposes other than understanding medical information, the platform does not assume relevant responsibilities. This platform does not mean that it agrees with its descriptions and views on the published content. If copyright issues are involved, please contact us, and we will deal with it as soon as possible.
![Gu Shaohua: The narrative of the "French Revolution" in late Qing China and its ideological implications[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)